Month: July 2020

SCOTTSDALE, Ariz., July 16, 2020 (GLOBE NEWSWIRE) — The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the “Company”), a producer of bottled alkaline water, flavored-infused waters, and CBD-infused products sold under the brand names Alkaline88®, A88 Infused™, and A88CBD™, respectively. The Company today announced that its hemp-derived cannabidiol brand A88CBD™ is partnering with consumer brands agency, C.A. Fortune.“A88CBD™ is growing rapidly, and we are excited for this partnership with C.A. Fortune so we can continue expanding the brand’s retail footprint,” stated Richard Wright, President and CEO of The Alkaline Water Company. “A88CBD™ boasts all-natural ingredients with a high-quality hemp-derived CBD formulation. C.A. Fortune works as one of the leading national brokers in the organic and all-natural space, and A88CBD™...

LA JOLLA, Calif, July 16, 2020 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced today the pricing of its  underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering price of $10.00 per share.   In addition, INmune has granted the underwriters an over-allotment option, exercisable for 45 days from today to purchase up to an additional 326,086 shares of common stock at the public offering price, less the underwriting discounts and commissions.  The offering is expected to close on or about July 20, 2020, subject to customary closing conditions.The gross proceeds to INmune from this offering are expected to...

SACRAMENTO, Calif., July 16, 2020 (GLOBE NEWSWIRE) — American River Bankshares (NASDAQ-GS: AMRB) today reported net income of $1.7 million, or $0.30 per diluted share for the second quarter of 2020 compared to $1.3 million, or $0.22 per diluted share for the second quarter of 2019.  For the six months ended June 30, 2020, net income was $3.2 million or $0.54 per diluted share, compared to $2.4 million or $0.41 per diluted share for the six months ended June 30, 2019.“As one would expect, the second quarter 2020 was significantly impacted by the COVID-19 pandemic.  Much of our activity was focused on addressing the issues caused by the pandemic,” said David E. Ritchie, Jr., President and Chief Executive Officer. “Our priority was keeping our staff and clients safe and helping our clients navigate this crisis through loan deferrals...

SEATTLE, July 16, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has contracted with Avance Clinical Pty Ltd to conduct a clinical study of Atossa’s proprietary drug candidate AT-301, to be administered by nasal spray. Avance is a leading Australian clinical research organization and has successfully completed multiple clinical studies of Atossa’s proprietary Endoxifen.AT-301 is Atossa’s proprietary formula intended for nasal administration in patients immediately following diagnosis of COVID-19 but who have not yet exhibited symptoms severe enough to require hospitalization. It is intended for at-home use...

CINCINNATI, July 16, 2020 (GLOBE NEWSWIRE) — LSI Industries (NASDAQ: LYTS) said today that the company has received Samsung’s Smart Signage Award for Food & Beverage Installation of the Year.  The award recognizes LSI for developing communication solutions for quick service restaurant (QSR) customers using innovative digital signage technology. “We are honored to receive this outstanding recognition from Samsung, and we thank them for being a trusted supplier and valued business partner,” said Jim Clark, President and CEO of LSI Industries.  “The award reflects our commitment to working closely with customers in order to understand their needs and deliver high-performance, innovative solutions.” As previously announced by LSI in April of 2020, a large QSR chain awarded the company new business valued at more than $100 million...

CDC reports UV-C Light Germicidal Irradiation (UVGI) as one of “most promising methods” for Coronavirus decontamination of facemasks.1RxAir400 employs powerful UVGI proven to inactivate >99.9% of viruses and pathogensReduces virus exposure risk in schools, restaurants, retail and office facilitiesWorcester, MA, July 16, 2020 (GLOBE NEWSWIRE) — Vystar Corporation (OTCQB: VYST) has restarted production of its RxAir®400 Ultraviolet (UV) light air purification systems with a new manufacturer that will enable enhanced reliability for supply chain, production and delivery. RxAir400 is a smaller, consumer/small business-sized version of the industrial size Rx3000 FDA-certified Class II medical device UV light air purifier designed for disinfection use in hospitals. Vystar anticipates receiving the first shipment of 10,000 RxAir400...

Oslo, 16 July 2020Interoil Exploration and Production ASA (the “Company”) has summoned a written resolution to introduce certain flexibility in the payment terms of the interests on the Senior Secured Callable Bonds with ISIN NO 001 0729908 (the “Bonds”).The proposed flexibility consists in the option of the Company to settle the payment of 50 per cent of the next three interest payments due and payable on 31 July 2020, 31 January 2021 and 31 July 2021, respectively, in kind by the issuance and delivery of new bonds with terms and conditions substantially equal to those of the outstanding bonds. The remaining 50 per cent of the interest payments due on 31 July 2020, 31 January 2021 and 31 July 2021, respectively, is to be settled in cash.Please see the attached summons for further background and a complete and detailed description of...

Invalda INVL, following the Rules for Granting Equity Incentives approved by the General Meeting of Shareholders on 1 July 2020 and pursuant to the decision of the said shareholders’ meeting on concluding option contracts with employees of Invalda INVL and of the companies, in which Invalda INVL owns 50 per cent or more of shares, signed option contracts for 232,210 ordinary registered shares of Invalda INVL AB.Invalda INVL concludes contracts on the issuance of share options to employees annually. On the basis of option contracts concluded in 2018, employees will be able to acquire up to 59,674 Invalda INVL shares in 2021, on the basis of option contracts concluded in 2019, employees will be able to acquire up to 70,397 shares in 2022, and on the basis of option contracts concluded on 1 June and 15 July this year, employees will...

Akcinė bendrovė „Invalda INVL“, vykdydama 2020 m. liepos 1 d. visuotiniame akcininkų susirinkime patvirtintų Akcijų suteikimo taisyklių nuostatas bei vadovaudamasi minėto akcininkų susirinkimo sprendimu dėl opcionų sutarčių sudarymo, su akcinės bendrovės „Invalda INVL“ ir įmonių, kurių daugiau kaip 50 proc. akcijų priklauso akcinei bendrovei „Invalda INVL“ darbuotojais sudarė opcionų sutartis dėl 232.210 paprastųjų vardinių akcinės bendrovės „Invalda INVL“ akcijų.„Invalda INVL“ sutartis dėl akcijų opcionų skyrimo darbuotojams sudaro kasmet. 2018 m. sudarytų opcionų sutarčių pagrindu darbuotojai 2021 m. galės įsigyti iki 59.674 „Invaldos INVL“ akcijų, 2019 m. sudarytų opcionų sutarčių pagrindu darbuotojai 2022 m. galės įsigyti iki 70.397 akcijų, o šių metų birželio 1 d. ir liepos 15 d. sudarytų opcionų sutarčių pagrindu darbuotojai 2023...